New developments in the therapy of ocular herpes simplex.
D000225:Adenine / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D001089:Arabinose / Q000627:therapeutic use; D006801:Humans; D007042:Hypoxanthines / Q000627:therapeutic use; D007065:Idoxuridine / Q000627:therapeutic use; D007369:Interferon Inducers / Q000627:therapeutic use*; D007372:Interferons / Q000627:therapeutic use; D007635:Keratitis, Dendritic / Q000628:therapy*; D009705:Nucleosides / Q000627:therapeutic use*; D011070:Poly I-C / Q000627:therapeutic use*
D000998:Antiviral Agents; D007042:Hypoxanthines; D007369:Interferon Inducers; D009705:Nucleosides; D007372:Interferons; D001089:Arabinose; D000225:Adenine; D007065:Idoxuridine; D011070:Poly I-C